Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

4.190 +0.180 (+4.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharma

< Previous 1 2 3 4 5 6 7 8 9 Next >
Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
INO earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why Inovio (INO) Shares Are Moving After-Hours
After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter financial... 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
2 Stocks to Sell or Remove From Your Watchlist in 2023
Both stocks soared during the coronavirus vaccine race, but their time has passed. 
Via The Motley Fool
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Inovio Pharmaceuticals (INO) Q3 2022 Earnings Call Transcript
INO earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why Inovio Pharmaceuticals' Shares Jumped 17.31% on Monday
The stock jumped Monday despite no news from the company. 
Via The Motley Fool
Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease
Via Benzinga
Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola
Inovio Pharmaceuticals Inc (NASDAQ: INO) announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a... 
Via Benzinga
3 Sorry Pharma Stocks to Sell in February Before It’s Too Late
These are the pharma stocks to sell, as they represent companies with weak fundamentals and sustained cash burn visibility. 
Via InvestorPlace
INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates
Via Benzinga
If You Invested $1,000 In Inovio Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two and a half years. But there was no question some big-name stocks performed... 
Via Benzinga
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Micron, Lexicon Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Westrock Coffee Company, LLC (NASDAQ: WEST) shares tumbled 10.9% to $11.90... 
Via Benzinga
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small... 
Via Benzinga
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in... 
Via Benzinga
Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious Disease Programs
Via Benzinga
3 Stocks to Avoid Right Now
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective. 
Via The Motley Fool
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Why Inovio Pharmaceuticals Stock Is Popping Off
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher by 9.11% to $2.34 after the company reported third-quarter financi 
Via Benzinga
What's Going On With Inovio Pharmaceuticals Stock Tuesday After Hours
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading marginally lower by 0.93% to $2.12 after the company reported  
Via Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases... 
Via Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster. 
Via The Motley Fool
Inovio Pharma Stops Work On INO-4800 As COVID-19 Heterologous Booster
Via Benzinga
Philips, Owens & Minor And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Tesla, Credit Suisse And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded mixed this morning after recording losses for the third quarter. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.